BeStock  
Stocks › Biotechnology › RXRX

Recursion Pharmaceuticals RXRX

US equityMarket cap rank #2863BiotechnologyAI medical concept stocks
$2.45 −$0.27 (-9.93%)
Market closed · Nov 21, 9:10 am ET · Last extended-hours $2.51 +2.39%
Open$2.63
Prev close$2.72
Day range$2.44 – $2.76
Volume29.88M
Market cap$1.53B
P/E (TTM)–
Dividend yield–

Fundamentals

Latest reported quarter: Q3, ended Sep 2026

Revenue$18.06M+262.3% YoY
Operating profit-$123.18M+28.5% YoY
Net profit-$119.04M+26.6% YoY
Diluted EPS-$0.22+38.9% YoY
Free cash flow-$77.81M+33.8% YoY
Operating cash flow-$77.41M

Revenue, last 8 quarters

$4.5MDec '24$14.8MMar '25$19.1MJun '25$5.0MSep '25$35.4MDec '25$6.3MMar '26$7.3MJun '26$18.1MSep '26

Net profit, last 8 quarters

$-178.9MDec '24$-202.5MMar '25$-171.9MJun '25$-162.3MSep '25$-108.1MDec '25$-117.5MMar '26$-131.0MJun '26$-119.0MSep '26

Diluted EPS by quarter

-0.53Dec '24-0.50Mar '25-0.41Jun '25-0.36Sep '25-0.21Dec '25-0.22Mar '26-0.25Jun '26-0.22Sep '26

Free cash flow by quarter

$-117.1MDec '24$-133.8MMar '25$-81.7MJun '25$-117.6MSep '25$-47.3MDec '25$-81.4MMar '26$-107.9MJun '26$-77.8MSep '26

Annual revenue

$3.4MFY20$10.0MFY21$39.7MFY22$43.9MFY23$58.5MFY24$74.3MFY25

Profitability & balance sheet

Gross margin27.9%
Operating margin-738.7%
Net margin-709.8%
Return on equity-48.7%
Return on assets-36.3%
Return on invested capital-47.1%
Current ratio5.01
Liabilities / assets25.9%
Cash & investments$549.85M
Total debt$62.44M
Net cash (debt)$487.42M

Income statement

Line item 2026 Q3 2026 Q2 2026 Q1 2025 ANNUAL 2025 Q4
Total Revenue as Reported $18.55M $7.67M $6.47M $74.68M $35.54M
Total Operating Revenue $18.06M $7.30M $6.30M $74.26M $35.35M
Cost of Revenue $10.05M $11.49M $12.49M $70.95M $14.28M
Gross Profit $8.01M -$4.19M -$6.19M $3.30M $21.08M
Operating Expense $131.19M $130.78M $122.32M $651.44M $129.41M
Selling and Admin Expenses $32.56M $41.53M $34.59M $176.59M $33.66M
-General & Admin Expense $32.56M $41.53M $34.59M $176.59M $33.66M
Research & Development $99.12M $89.61M $87.90M $475.27M $95.94M
Other Operating Expenses -$497,000.00 -$367,000.00 -$171,000.00 -$425,000.00 -$187,000.00
Operating Profit -$123.18M -$134.97M -$128.51M -$648.13M -$108.33M
Net Non-Operating Interest Income (Expense) $4.55M $5.00M $5.61M $20.98M $6.26M
Non-Operating Interest Income $4.82M $5.31M $5.96M $22.79M $6.25M
Non-Operating Interest Expense $266,000.00 $309,000.00 $350,000.00 $1.81M -$11,000.00
Other Income (Expense) -$385,000.00 -$1.04M $784,000.00 -$17.74M -$6.03M
Other Non-Operating Income (Expenses) -$385,000.00 -$1.04M $784,000.00 -$17.74M -$6.03M
Pretax Profit -$119.01M -$131.01M -$122.11M -$644.90M -$108.10M
Tax $25,000.00 -$1,000.00 -$4.60M -$136,000.00 $20,000.00
Net Profit -$119.04M -$131.01M -$117.50M -$644.76M -$108.12M
Profit from Continuing Operations -$119.04M -$131.01M -$117.50M -$644.76M -$108.12M
Net Income to Parent Company -$119.04M -$131.01M -$117.50M -$644.76M -$108.12M
Net Income to Common Stockholders -$119.04M -$131.01M -$117.50M -$644.76M -$108.12M
Basic EPS -$0.22 -$0.25 -$0.22 -$1.44 -$0.21
Diluted EPS -$0.22 -$0.25 -$0.22 -$1.44 -$0.21

Balance sheet

Line item 2026 Q3 2026 Q2 2026 Q1 2025 ANNUAL 2025 Q4
Total Assets $1.22B $1.21B $1.34B $1.47B $1.47B
Total Current Assets $616.02M $603.46M $709.56M $812.85M $812.85M
Cash and Cash Equivalents & Short-Term Investments $549.85M $545.68M $654.47M $743.29M $743.29M
-Cash and Cash Equivalents $549.85M $545.68M $654.47M $743.29M $743.29M
Receivables $34.07M $14.39M $13.59M $24.65M $24.65M
-Other Receivables $34.07M $14.39M $13.59M $24.65M $24.65M
Prepaid Assets $2.88M $8.68M $11.74M $11.74M $11.74M
Restricted Cash $6.66M $5.39M $5.51M $4.59M $4.59M
Other Current Assets $22.56M $29.32M $24.25M $28.57M $28.57M
Total Non-Current Assets $605.69M $609.21M $629.97M $661.29M $661.29M
Net PPE $152.70M $147.07M $157.32M $169.48M $169.48M
-Gross PPE $152.70M $147.07M $157.32M $258.69M $258.69M
Goodwill and Other Intangible Assets $434.39M $443.24M $454.24M $472.06M $472.06M
-Goodwill $160.71M $160.35M $160.17M $162.16M $162.16M
-Other Intangible Assets $273.68M $282.89M $294.07M $309.90M $309.90M
Non-Current Deferred Assets $957,000.00 $957,000.00 $957,000.00 $957,000.00 $957,000.00
Other Non-Current Assets $17.65M $17.94M $17.44M $18.79M $18.79M
Total Liabilities $315.90M $297.67M $314.75M $343.27M $343.27M
Total Current Liabilities $122.92M $119.89M $129.70M $147.71M $147.71M
Payables $20.37M $16.23M $20.35M $18.12M $18.12M
-Accounts Payable $16.38M $12.67M $20.35M $18.12M $18.12M
-Total Tax Payable $3.99M $3.56M – – –
Current Accrued Expenses $34.43M $33.51M $39.64M $38.46M $38.46M
Short-Term Debt and Capital Lease Obligation $24.07M $22.69M $22.35M $21.75M $21.75M
-Current Debt $11.81M $9.44M $9.27M $9.09M $9.09M
-Current Capital Lease Obligation $12.26M $13.25M $13.09M $12.66M $12.66M
Current Deferred Liabilities $18.97M $29.50M $32.79M $37.61M $37.61M
Total Non-Current Liabilities $192.98M $177.78M $185.05M $195.56M $195.56M
Long Term Debt and Capital Lease Obligation $50.63M $43.95M $50.02M $56.21M $56.21M
-Long Term Debt $93,000.00 $4.75M $7.18M $9.56M $9.56M
-Long Term Capital Lease Obligation $50.54M $39.19M $42.84M $46.65M $46.65M
Non-Current Deferred Liabilities $138.39M $131.13M $133.01M $137.27M $137.27M
Other Non-Current Liabilities $3.96M $2.70M $2.03M $2.08M $2.08M
Total Equity $905.81M $915.00M $1.02B $1.13B $1.13B
Stockholders' Equity $905.81M $915.00M $1.02B $1.13B $1.13B
Capital Stock $6,000.00 $5,000.00 $5,000.00 $5,000.00 $5,000.00
-Common Stock $6,000.00 $5,000.00 $5,000.00 $5,000.00 $5,000.00
Additional Paid-In Capital $3.32B $3.21B $3.19B $3.17B $3.17B
Retained Earnings -$2.44B -$2.32B -$2.19B -$2.08B -$2.08B
Gains/Losses Not Affecting Retained Earnings $29.63M $27.99M $26.66M $36.72M $36.72M
-Accumulated Depreciation – – – -$89.21M -$89.21M

Cash flow

Line item 2026 Q3 2026 Q2 2026 Q1 2025 ANNUAL 2025 Q4
Operating Cash Flow -$77.41M -$105.95M -$81.10M -$371.81M -$46.07M
Net cash flow from continuing operations -$77.41M -$105.95M -$81.10M -$371.81M -$46.07M
Net Income from Continuing Operations -$119.04M -$131.01M -$117.50M -$644.76M -$108.12M
Depreciation & Depletion & Amortization $16.54M $18.17M $19.67M $83.70M $19.48M
Deferred Tax $0.00 -$3,000.00 -$4.60M – –
Other Non-Cash Items $6.28M $5.96M $6.92M $53.88M $30.43M
Change in Working Capital -$4.21M -$18.56M -$7.81M $13.69M $10.68M
-Change in Receivables -$13.88M -$6.29M $14.75M $32.94M -$836,000.00
-Change in Prepaid Assets $5.80M $3.06M $0.00 $49.86M $20.26M
-Change in Payables and Accrued Expense $13.56M -$3.39M -$15.65M -$12.35M $1.88M
-Change in Other Current Liabilities -$4.63M -$4.64M -$4.65M -$19.99M -$3.86M
-Change In Other Working Capital -$5.05M -$7.30M -$2.25M -$36.77M -$6.76M
Net cash flow from investing -$407,000.00 -$1.96M -$338,000.00 -$16.87M -$1.24M
Net Cash Flow from Continuing Investing Activities -$407,000.00 -$1.96M -$338,000.00 -$16.87M -$1.24M
Net PPE Purchase and Sale -$407,000.00 -$44,000.00 -$258,000.00 -$6.47M -$1.24M
Net Intangibles Purchase and Sale $0.00 -$1.92M -$80,000.00 -$2.16M $0.00
Net Business Purchase and Sale $0.00 $0.00 $0.00 -$4.44M $0.00
Net Investment Purchase and Sale $0.00 $0.00 $0.00 -$3.81M $0.00
Financing Cash Flow $83.14M -$1.27M -$3.47M $521.53M $132.01M
Net Cash Flow from Continuing Financing Activities $83.14M -$1.27M -$3.47M $521.53M $132.01M
Net Issuance Payments Of Debt -$2.29M -$2.25M -$2.21M -$8.43M -$2.17M
Net Common Stock Issuance $85.52M $0.00 $0.00 $528.86M $133.38M
Proceeds from Stock Option Exercised -$77,000.00 $984,000.00 -$1.26M $4.09M $793,000.00
Ending Cash Balance $561.53M $556.82M $665.18M $753.92M $753.92M
Net Change in Cash $5.33M -$109.17M -$84.91M $132.85M $84.69M
Beginning Cash Balance $556.82M $665.18M $753.92M $603.02M $667.15M
Effect of Exchange Rate Changes -$621,000.00 $813,000.00 -$3.83M $18.04M $2.09M
Free Cash Flow -$77.81M -$107.91M -$81.44M -$380.44M -$47.32M
Gain/Loss from Continuing Operations – – – $4.50M -$22.08M
Net Other Financing Charges – – – -$3.00M $0.00

Discussion

No comments yet — be the first to weigh in on RXRX.

Sign in to join the discussion.

Scroll to Top